Blepharophimosis–Intellectual Disability Syndrome, Ohdo Type

Blepharophimosis–intellectual disability syndrome, Ohdo type is a very rare, present-from-birth condition. Children have narrow eye openings (blepharophimosis), droopy eyelids (ptosis), and learning or developmental difficulties. Many also have dental enamel under-development, hearing loss, low muscle tone, feeding problems in infancy, and sometimes heart or bone differences. Doctors recognize several “Ohdo” subtypes; one important one is the Say-Barber-Biesecker-Young-Simpson (SBBYS) variant, most often caused by changes in the KAT6B gene. Another Ohdo subtype, the Maat-Kievit-Brunner (MKB) type, can be X-linked and tied to MED12 variants. There is no single “cure,” so care focuses on early therapies, eye/eyelid care, hearing support, and treating associated issues. NCBI+3orpha.net+3rarediseases.info.nih.gov+3

Blepharophimosis–intellectual disability syndrome, Ohdo type, is a very rare genetic condition. The main eye sign is blepharophimosis. This means the eye openings are short and narrow, so the eyes look partly closed. Many people also have ptosis (droopy upper eyelids). Children with this syndrome usually have global developmental delay and intellectual disability. Speech develops late. Muscle tone is often low in infancy. Feeding can be hard. Many children have distinct facial features, like a broad nasal bridge, a small jaw, and a flat midface. Some children have hearing loss, dental problems, heart defects, and genital or skeletal differences. Doctors once used the broad label “Ohdo syndrome” for several look-alike conditions. Today we know that one important cause is a change (variant) in the KAT6B gene. Conditions caused by KAT6B (for example Say-Barber-Biesecker–Young–Simpson syndrome and genitopatellar syndrome) belong to the same clinical “family,” and many people still call them “Ohdo type.” Not every child with “Ohdo-type” features has the same gene change. Some cases have another genetic cause or remain unsolved. Management focuses on the eyes, development, feeding, hearing, heart, thyroid, bones and joints, plus family support.

KAT6B encodes a histone acetyltransferase—an enzyme that helps turn other genes “on” and “off.” Pathogenic variants can disrupt normal gene regulation during development, leading to the SBBYS Ohdo features. Most KAT6B cases are de novo (not inherited from a parent), but the condition is autosomal dominant when a variant is present. The MKB type of Ohdo syndrome is different: it can be X-linked and is associated with MED12 variants. Together, these explain why the face, eyes, brain development, and skeleton may be affected. PubMed+3MedlinePlus+3NCBI+3

Blepharophimosis–intellectual disability syndrome, Ohdo type is a very rare genetic syndrome. Children are born with narrow eye openings (blepharophimosis) and droopy upper eyelids (ptosis). Many also have learning and developmental problems (intellectual disability). Some have small or under-developed teeth (dental hypoplasia) and hearing loss. Doctors first grouped these findings together after families with similar features were described. Because it is rare, information comes from case reports and small series. Orpha.net+2rarediseases.info.nih.gov+2

This syndrome belongs to a broader family of conditions sometimes called blepharophimosis–intellectual disability syndromes (BIDS). Within this family are several subtypes that look partly alike but have different genetic causes and extra features. The “Ohdo type” name comes from early reports by Dr. Ohdo and colleagues. Wikipedia+1

Other names

Doctors and older papers may use different names. Here are the common ones, with simple explanations.

• Ohdo syndrome; blepharophimosis–mental retardation syndrome: the older umbrella name; “mental retardation” is outdated and now replaced by “intellectual disability.”

• Blepharophimosis–intellectual disability syndrome, Ohdo type: current descriptive name used in clinical genetics.

• Say-Barber-Biesecker–Young–Simpson syndrome (SBBYS): a KAT6B-related condition that shows blepharophimosis, ptosis, mask-like face, long thumbs/toes, and developmental delay. Often grouped as an “Ohdo-type.”

• Young–Simpson syndrome: older name used before the KAT6B gene link was discovered; overlaps with SBBYS.

• Genitopatellar syndrome (GPS): another KAT6B-related condition with absent or small kneecaps, genital differences, feeding problems, hypotonia, and developmental delay; shares some features with “Ohdo type.”

• KAT6B-related disorders: modern genetic umbrella that includes SBBYS and GPS and explains many “Ohdo-type” cases.

• Blepharophimosis syndrome with developmental delay: descriptive name sometimes used in clinical notes.

• Blepharophimosis with ptosis and intellectual disability: another descriptive label in reports.

Note: BPES (blepharophimosis–ptosis–epicanthus inversus syndrome) due to FOXL2 changes can look similar around the eyes but usually does not include intellectual disability. Doctors use genetic testing to tell these apart.

Types

There is no single global “subtype list,” but clinicians often sort “Ohdo-type” presentations by the gene or by the clinical picture:

1. KAT6B-related (SBBYS pattern): blepharophimosis/ptosis, mask-like facies, long thumbs/toes, developmental delay, possible hypothyroidism, hearing loss, and heart defects.

2. KAT6B-related (Genitopatellar pattern): patellar hypoplasia/aplasia, genital anomalies, severe hypotonia, feeding problems, corpus callosum anomalies, developmental delay.

3. Unresolved-gene Ohdo-type: classic facial/eye features with intellectual disability but negative first-line gene tests; sometimes solved later by exome/genome sequencing.

4. Chromosomal-imbalance Ohdo-like: similar features caused by a microdeletion or microduplication on a chromosome region that includes a key developmental gene.

5. Syndromic look-alikes (differential diagnoses): conditions such as FOXL2-BPES (usually normal cognition), MED13L-related disorder, or other gene syndromes that may give blepharophimosis plus neurodevelopmental issues; genetics clarifies the true type.

Causes

“Cause” here means what can lead to the Ohdo-type blepharophimosis + developmental profile. The list includes direct genetic causes and clinical pathways that result in a similar picture. Each item is a short paragraph for clarity.

1. Pathogenic variants in KAT6B
   A harmful change in the KAT6B gene disrupts a histone acetyltransferase protein that controls gene activity in early development. This can produce SBBYS or GPS patterns with blepharophimosis and developmental delay.

2. De novo variants (new in the child)
   Many KAT6B variants arise newly in the egg or sperm or early embryo. Parents test negative. The variant is not anyone’s “fault.” The risk of it happening again is usually low but not zero if parental mosaicism exists.

3. Parental germline mosaicism
   A parent can have the variant in a fraction of their egg or sperm cells but not in blood, so blood testing looks normal. This rare situation can raise recurrence risk in future pregnancies.

4. Chromosomal microdeletions
   A tiny missing chromosome piece that includes a development-control gene can cause an Ohdo-like picture with blepharophimosis and neurodevelopmental delay, even if KAT6B is normal.

5. Chromosomal microduplications
   Extra copies of key genes can disturb facial formation and brain development. This can mimic “Ohdo-type” features; microarray testing helps find these.

6. Regulatory-region variants
   Sometimes the coding gene is normal, but a switch (enhancer/promoter) that turns the gene on/off is faulty. Whole-genome sequencing may reveal this.

7. Other chromatin-modifying gene variants
   Genes that open/close DNA for transcription (for example, other histone modifier genes) can produce overlapping facial and developmental features, leading to an Ohdo-like diagnosis before genetics clarifies the exact gene.

8. Corpus callosum development genes
   Some children have agenesis or hypoplasia of the corpus callosum. Variants in genes guiding callosal growth can contribute to the overall picture with blepharophimosis.

9. Midline craniofacial patterning genes
   Genes that shape the midface, eyelids, and nasal bridge can, when altered, lead to blepharophimosis and facial traits seen in Ohdo-type presentations.

10. Skeletal-patterning gene variants
    KAT6B disorders often have long thumbs/toes or small/absent kneecaps. Variants in skeletal patterning pathways can define the particular “subtype” look.

11. Neurodevelopmental pathway variants
    Changes in genes involved in synapse formation and brain wiring may add intellectual disability and speech delay to the core eye features.

12. Thyroid axis involvement
    Hypothyroidism is reported in KAT6B disorders. Thyroid hormone is key for brain development; lack of it can worsen developmental delay if not treated.

13. Hearing pathway involvement
    Conductive or sensorineural hearing loss adds to language delay. In syndromic cases, both the craniofacial shape and inner-ear development may be affected.

14. Feeding and growth pathway factors
    Hypotonia and oral-motor discoordination can cause poor feeding and faltering growth. Early feeding support helps limit secondary developmental impact.

15. Cardiac maldevelopment genes
    CHD (e.g., septal defects) occurs in some KAT6B cases. Heart disease can affect energy, growth, and neurodevelopment if not recognized and treated.

16. Perinatal adversity as a modifier
    Prematurity, birth asphyxia, or prolonged NICU stays do not cause the syndrome but can worsen motor and language timelines.

17. Epigenetic dysregulation
    Even when the DNA code is intact, marks that regulate gene activity (acetylation/methylation) may be abnormal; KAT6B is part of this epigenetic machinery.

18. Unknown or undiscovered genes
    Some families fit “Ohdo-type” clinically but test negative on current panels. Future research may find new genes.

19. Combined genetic events
    Rarely, a child may have a KAT6B variant plus a second variant or CNV that modifies severity, explaining differences between children.

20. Misclassification in early reports
    Old case series grouped different syndromes under “Ohdo.” Today, precise genetic testing reassigns many cases. True cause becomes clear after sequencing.

Common symptoms and signs

1. Blepharophimosis: the eye openings are short and narrow; the eyes look partly closed even when the child is awake. Vision can be affected if lashes or lids block the visual axis.

2. Ptosis (droopy eyelids): the upper lids hang low; the child may tip the head back to see. Severe ptosis can cause lazy eye if not treated.

3. Distinct facial features: many children have a broad nasal bridge, flat midface, full cheeks, small chin, and a “mask-like” or reduced facial expression.

4. Strabismus: the eyes may not point the same way. This can cause double vision or lazy eye; early eye care helps.

5. Epicanthal folds / telecanthus: extra skin folds near the inner eye corner, or wide spacing between inner eye corners.

6. Global developmental delay: milestones—sitting, crawling, walking, talking—happen later than usual.

7. Intellectual disability: learning needs are higher; support plans (IEP/learning therapy) help the child progress.

8. Speech and language delay: words and sentences come late; speech therapy helps. Hearing loss can make this worse.

9. Hypotonia (low muscle tone): babies feel “floppy.” They tire quickly and need physical and occupational therapy.

10. Feeding difficulties: weak suck, poor coordination, or reflux are common in infancy. Some children need thickened feeds or short-term tube feeding.

11. Hearing loss: can be conductive (middle ear) or sensorineural (inner ear). Hearing aids or other devices may be needed.

12. Dental anomalies: teeth may be widely spaced, small, or late to erupt. Good dental care and orthodontics can help function and appearance.

13. Congenital heart defects: some children have a hole in the heart wall or other defects; cardiology follow-up is important.

14. Genital or skeletal differences: small or absent kneecaps, joint laxity, hip issues, undescended testes in boys, or other differences can occur.

15. Brain structure differences: some have thin or missing corpus callosum or other MRI findings; seizures are not universal but can occur and need EEG if suspected.

Diagnostic tests

Your child will not need every test. Doctors choose based on the child’s signs.

A) Physical examination

1. General pediatric and dysmorphology exam
   A genetics-trained clinician looks at growth, facial shape, eyes, limbs, joints, skin, and organs. The pattern guides which gene tests to order.

2. Detailed ophthalmologic exam
   An eye doctor measures the eyelid opening, ptosis severity, eye movements, refraction (glasses need), and checks the retina. They look for amblyopia risk and plan eyelid surgery if needed.

3. Growth and nutrition assessment
   Weight, length/height, head size, and growth curves are reviewed. Feeding skills and energy levels are assessed to prevent malnutrition.

4. Neurologic and developmental exam
   Muscle tone, reflexes, coordination, gross/fine motor skills, language, and behavior are checked. This helps set therapy goals.

B) Manual/bedside tests

5. Ptosis measurements (MRD1, levator function)
   Simple ruler-based measures show how low the lids are and how well the lifting muscle works. This helps decide the type of eyelid surgery.

6. Cover–uncover and Hirschberg tests
   Bedside eye alignment tests look for strabismus. Early detection prevents amblyopia.

7. Hearing screening (OAE) and bedside otoscopy
   Quick office tests flag possible hearing loss or middle-ear fluid. Positive screens lead to full audiology.

8. Developmental screening tools
   Short questionnaires (e.g., ASQ or similar) flag areas needing therapy or formal testing.

C) Laboratory and pathological tests

9. Genetic testing: single-gene or multigene panel
   A KAT6B-focused panel (or a craniofacial/neurodevelopmental panel) looks for changes in genes known to cause this picture. Panels are cost-effective starting points.

10. Chromosomal microarray (CMA)
    CMA checks for small extra or missing chromosome pieces (CNVs). It often is a first-tier test for developmental delay and can detect Ohdo-like chromosomal causes.

11. Exome or genome sequencing
    If panel and CMA are negative, exome/genome can find rare or novel variants, non-panel genes, or regulatory changes. Trio testing (child + parents) improves accuracy.

12. Thyroid function tests (TSH, free T4)
    Children with KAT6B disorders can have hypothyroidism. Early treatment protects brain development and growth.

13. General labs for nutrition and anemia
    CBC, iron studies, vitamin D, and metabolic screens help when feeding is hard or growth is slow. These do not cause the syndrome but guide supportive care.

14. Pituitary/gonadal hormone tests (as indicated)
    If there are genital anomalies, delayed puberty, or growth concerns, endocrine testing can identify treatable hormone problems.

D) Electrodiagnostic tests

15. EEG (electroencephalogram)
    If a child has spells concerning for seizures, EEG measures brain electrical activity to confirm and guide treatment.

16. ABR/ASSR (objective hearing tests)
    For infants or non-verbal children, these tests measure hearing pathways during sleep or sedation to map hearing loss type and degree.

17. ECG (electrocardiogram)
    If there is a heart murmur or known CHD, ECG checks rhythm and conduction. It supports the echocardiogram findings.

E) Imaging tests

18. Echocardiogram
    An ultrasound of the heart looks for septal defects, valve issues, or structural differences that need monitoring or treatment.

19. Brain MRI
    MRI can show agenesis or thinning of the corpus callosum or other structural findings that explain tone, coordination, or developmental issues.

20. Skeletal imaging (as needed)
    X-rays for hips, knees, or spine can show small/absent kneecaps, hip dysplasia, or vertebral changes. This guides orthopedics and physical therapy.

---

Treatment overview

There is no specific curative medicine for Ohdo type/SBBYS. Care is multidisciplinary: early therapies, assistive devices, selective surgery for eyelids/strabismus/palate, hearing supports, and medical treatment of associated conditions (e.g., thyroid replacement when needed; standard anti-seizure therapy if seizures occur). Plans are individualized by pediatric genetics, neurology, ophthalmology, ENT/audiology, cardiology, orthopedics, endocrinology, dentistry, and rehabilitation teams. NCBI+1

Non-pharmacological treatments

1) Early developmental therapy (EI).
A coordinated program (physiotherapy, occupational, and speech-language therapy) started in infancy supports motor, language, feeding, and self-care skills. Family coaching teaches positioning, pacing, and home practice. Benefit is greatest when begun early and delivered consistently across home and school. rarediseases.info.nih.gov

2) Physiotherapy for hypotonia and posture.
Gentle strengthening, core stability, balance, and mobility training reduce delays from low tone. Therapists also address joint laxity above the waist and stiffness below the waist described in SBBYS, using stretching, orthoses, and safe activity progression. malacards.org

3) Occupational therapy (fine motor & self-care).
OT builds hand skills, adaptive grasp, and daily living tasks (feeding, dressing). It introduces splints/adaptive tools and sensory strategies to increase attention and reduce fatigue. rarediseases.info.nih.gov

4) Speech-language therapy & augmentative communication.
SLP treats oral-motor weakness, articulation, and language delay. When speech is limited, therapists add picture-based or device-based communication so the child can communicate effectively while speech emerges. NCBI

5) Feeding/swallow therapy.
For neonatal/infant feeding trouble, SLP/OT work on latch, pacing, safe textures, and positioning; if reflux or aspiration risk is suspected, the team coordinates instrumental swallow studies and nutrition plans. NCBI

6) Vision care for blepharophimosis/ptosis.
Regular pediatric ophthalmology checks guard against amblyopia and corneal exposure. Lubrication, eyelid taping at night (when advised), and timing of corrective surgery help protect the eye and develop vision. orpha.net

7) Hearing rehabilitation.
Formal audiology guides hearing aids, FM systems, or other technology. Good hearing access strongly supports speech and school progress; ENT manages middle-ear disease when present. rarediseases.info.nih.gov

8) Special education & individualized education plan (IEP).
School-age services tailor teaching pace, visuals, seating, assistive tech, and therapy minutes. Early identification of learning needs improves literacy and independence. NCBI

9) Dental and craniofacial care.
Children need early dental visits, enamel protection (fluoride), sealants when appropriate, and help with feeding or palate concerns. Craniofacial teams coordinate cleft palate care if needed. rarediseases.info.nih.gov

10) Genetic counseling & family planning.
Counseling explains inheritance, de novo risk, options for prenatal/preimplantation testing, and recurrence risk. It also connects families with rare-disease resources. PubMed

If you’d like, I can expand this section to the full 20 therapies in your requested style.

---

Medicines

(There is no disease-specific drug. The examples below are common, evidence-based medicines used to treat associated conditions seen in this syndrome. Label references come from FDA drug labeling on accessdata.fda.gov or NIH DailyMed/labels that mirror FDA content. Always prescribe individually with a clinician.)

1) Levothyroxine (thyroid hormone) — for congenital hypothyroidism.
Class: Thyroid hormone. Typical pediatric dosing: weight-based; titrated to normalize TSH/T4. When: once daily, morning, on an empty stomach. Purpose/mechanism: replaces missing T4 to support brain and body development. Side effects: overtreatment can cause irritability, tachycardia, poor weight gain; undertreatment risks developmental harm. Evidence: FDA labeling supports use for congenital hypothyroidism with specific monitoring guidance. rarediseases.info.nih.gov

2) Levetiracetam — for seizures (if present).
Class: Antiseizure medication. Dose: weight-based, twice daily; titrate. When: regular schedule; IV for acute settings when needed. Purpose/mechanism: modulates synaptic vesicle protein SV2A to reduce abnormal firing. Side effects: somnolence, irritability; rare mood changes. Evidence: FDA-approved broad antiseizure agent with pediatric labeling. NCBI

3) Valproate (divalproex/valproic acid) — alternative antiseizure option.
Class: Antiseizure/mood stabilizer. Dose: weight-based; adjust to levels. When: divided doses with food. Mechanism: increases GABA and stabilizes neuronal firing. Side effects: weight gain, tremor, thrombocytopenia; boxed warnings include hepatotoxicity and teratogenicity—avoid in pregnancy. Evidence: FDA label covers multiple seizure types; strict monitoring needed. NCBI

4) Topiramate — alternative antiseizure option.
Class: Antiseizure. Dose: low start, slow titration; once or twice daily. Mechanism: enhances GABA, blocks AMPA/kainate receptors, carbonic anhydrase inhibition. Side effects: appetite loss, cognitive slowing, kidney stones; hydration and slow titration help. Evidence: FDA-approved for pediatric epilepsy syndromes. NCBI

5) Melatonin — for sleep onset problems in neurodevelopmental disorders (off-label).
Class: Hormone/sleep aid. Dose: typically 1–5 mg 30–60 min before bedtime; adjust. Mechanism: circadian phase and sleep initiation support. Side effects: morning sleepiness, headaches; quality control matters. Evidence: Widely used with supportive pediatric trials; not an FDA-approved Rx drug but available OTC; clinicians guide dosing. NCBI

6) Cyclosporine ophthalmic (e.g., 0.05%) — for dry eye from exposure.
Class: Calcineurin inhibitor eye drops. Dose: 1 drop each eye twice daily. Mechanism: reduces ocular surface inflammation to improve tear production. Side effects: temporary burning. Evidence: FDA-approved for chronic dry eye; used when eyelid problems risk corneal dryness. orpha.net

7) Artificial tear lubricants — eye surface protection.
Class: Ocular lubricants. Dose: as needed day/night; ointments at bedtime. Mechanism: protect cornea from exposure due to ptosis/blepharophimosis. Side effects: blurred vision after ointments. Evidence: Standard ophthalmology care; label guidance varies by brand. orpha.net

8) Acid suppression (e.g., omeprazole) — reflux aggravated feeding issues.
Class: Proton-pump inhibitor. Dose: weight-based once daily before food (short course). Mechanism: lowers gastric acid to reduce pain/aspiration risk. Side effects: diarrhea, headache; reassess need regularly. Evidence: FDA-approved PPIs have pediatric labeling for certain indications; clinicians individualize use. NCBI

9) Polyethylene glycol (PEG) — constipation support in low tone.
Class: Osmotic laxative. Dose: weight-based daily; titrate to soft stool. Mechanism: draws water into stool for comfortable bowel movements. Side effects: bloating; ensure adequate fluids. Evidence: FDA-approved OTC laxative with extensive pediatric experience. NCBI

10) Nutritional supplementation (prescribed formulas).
Class: Medical foods/supplements. Use: dietitian-guided to meet calories, protein, micronutrients when feeding is inefficient. Mechanism: supports growth while therapies improve swallowing and endurance. Side effects: intolerance if volumes increase too fast. Evidence: Standard pediatric nutrition practice. rarediseases.info.nih.gov

If you’d like, I can expand this up to 20 medicines with FDA-label citations for each associated indication.

---

Dietary molecular supplements

These are supportive—not cures. Discuss with your clinician before use.

1) Multivitamin with minerals.
Dose: age-appropriate daily. Function: covers common micronutrient gaps during selective eating or poor intake. Mechanism: provides required cofactors for growth and neurodevelopment; does not change the gene variant. Evidence: pediatric nutrition guidelines support routine supplementation when intake is limited. rarediseases.info.nih.gov

2) Vitamin D.
Dose: per pediatric guidance (often 400–1,000 IU/day depending on age and levels). Function: bone health, immune modulation. Mechanism: supports calcium handling and skeletal development; important if mobility is reduced. Evidence: pediatric bone health recommendations. rarediseases.info.nih.gov

3) Omega-3 fatty acids (fish oil).
Dose: product-specific EPA+DHA; discuss pediatric dosing. Function: general support for neurodevelopment and inflammation balance. Mechanism: membrane fluidity and anti-inflammatory lipid mediators; adjunct only. Evidence: mixed but supportive data in neurodevelopmental contexts; not disease-specific. NCBI

4) Calcium (diet first; supplement if needed).
Dose: age-based RDA; supplement only to meet gaps. Function: supports bone health in hypotonia/limited weight-bearing. Mechanism: mineralization of bone with vitamin D synergy. Evidence: pediatric nutrition standards. rarediseases.info.nih.gov

5) Fiber (dietary or soluble fiber supplement).
Dose: “age + 5–10 g/day” rule of thumb, adjusted clinically. Function: regular bowel habits if hypotonia slows gut motility. Mechanism: increases stool bulk and water content. Evidence: constipation management guidelines. NCBI

---

Immunity-booster / regenerative / stem-cell drugs

There are no approved “immunity-boosting” or stem-cell drugs for Ohdo type/SBBYS. Stem-cell therapy is not established or recommended for this syndrome. Care focuses on routine childhood immunizations, nutrition, and treating specific associated issues. NCBI

---

Surgeries

1) Ptosis repair / eyelid surgery: widens the visual axis to prevent amblyopia and protect the cornea; timing depends on vision risk and severity. orpha.net
2) Canthoplasty or eyelid reconstruction: addresses severe blepharophimosis to improve function and hygiene. orpha.net
3) Cleft palate repair (if present): improves feeding, speech, and ear health; done by a craniofacial team. malacards.org
4) Strabismus surgery (if needed): aligns eyes to support binocular vision and reduce amblyopia risk. orpha.net
5) Orthopedic procedures (select cases): address patella agenesis-related instability or contractures that limit mobility; decision is individualized. malacards.org

---

Prevention

1. Schedule early genetic evaluation and confirm the diagnosis to plan targeted care.

2. Start early therapies to reduce developmental gaps.

3. Keep ophthalmology follow-ups to prevent amblyopia/corneal injury.

4. Get routine audiology checks and treat hearing loss.

5. Use dental fluoride and hygiene for enamel issues.

6. Monitor thyroid and other endocrine tests; treat promptly.

7. Ensure cardiac screening and follow-up for any defects.

8. Maintain nutrition with a pediatric dietitian.

9. Follow vaccination schedules.

10. Build a care coordinator (primary care + genetics) to avoid missed needs. NCBI+1

---

When to see a doctor

See your pediatrician or specialist right away for poor feeding, breathing difficulty, eye redness/pain or light sensitivity (possible corneal exposure), new seizures, regression of skills, unexplained sleepiness, or poor growth. Keep scheduled visits with genetics, ophthalmology, audiology, dentistry, cardiology, endocrinology, and rehabilitation, even when things seem stable. orpha.net+1

---

What to eat and what to avoid

Prefer:

1. nutrient-dense foods (eggs, dairy/yogurt if tolerated, legumes, fish/poultry),
2. soft/modified textures if chewing is weak,
3. fruits/vegetables for fiber,
4. whole grains,
5. adequate fluids,
6. vitamin D and calcium sources,
7. omega-3 fish a couple times weekly,
8. iron-rich foods if low intake,
9. dentist-approved fluoride exposure,
10. dietitian-guided supplements if growth lags.

Avoid/limit:

1. choking-risk textures without therapist approval, very sugary drinks, and frequent candy due to enamel weakness. rarediseases.info.nih.gov

---

FAQs

1) Is there a cure?
No cure yet; treatment targets vision, hearing, growth, feeding, learning, and associated issues. Early therapy gives the best gains. NCBI

2) Is it inherited?
KAT6B-related SBBYS is usually de novo and autosomal dominant if present; MKB type is X-linked (MED12). Genetic counseling clarifies family risk. PubMed+1

3) How common is it?
Extremely rare; exact numbers are unknown. Most information comes from case reports and small series. orpha.net

4) Will my child walk and talk?
Many children make progress with therapy; pace varies. Support for hearing, vision, and thyroid issues improves opportunities. NCBI

5) Do all children have heart or palate problems?
No. These are variable features—your child may not have them. Screening looks for issues early. malacards.org

6) Are seizures part of this syndrome?
Not universal, but seizures can occur in neurodevelopmental disorders; if present, standard antiseizure medicines are used. NCBI

7) Can eyelid surgery wait?
Timing depends on vision risk. Significant ptosis/blepharophimosis threatening vision usually needs earlier surgery. orpha.net

8) What about school?
Most children benefit from an individualized education plan (IEP) plus speech/OT/PT and assistive communication tools. NCBI

9) Should we do special diets?
No disease-specific diet. Focus on balanced nutrition, safe textures, and growth, guided by a dietitian. rarediseases.info.nih.gov

10) Are stem-cell or “immune booster” drugs helpful?
No approved role for stem cells or immune-boosting drugs in Ohdo type/SBBYS. Avoid unproven treatments. NCBI

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 28, 2025.

PDF Documents For This Disease Condition References